Clinical Trials | June 15, 2024
Sun Pharma and Moebius Medical present Phase 2b study on MM-II
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Further strengthens BaseLaunch's global pharma industry partnerships
Subscribe To Our Newsletter & Stay Updated
